 LONDON and RALEIGH, N.C., Dec. 19, 2022 GLOBE NEWSWIRE -- Verona Pharma plc Nasdaq: VRNA Verona Pharma or the Company, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it will report top-line Phase 3 data from its ENHANCE-1 trial of nebulized ensifentrine on Tuesday, December 20, 2022. The Company will host an investment community webcast and conference call at 8:30 a.m. EST 1:30 p.m. GMT to discuss these data. 